This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
nash
NASH
Metabolic liver disease from steatosis (NAFLD) through steatohepatitis (NASH) to fibrosis and HCC; driven by insulin resistance and hepatic lipid overload. TGF-beta activates stellate cells → fibrosis; semaglutide and resmetirom (THR-beta agonist) are approved treatments.
Entry Metadata
| Field | Value |
|---|---|
| ID | nash |
| Name | NASH |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. · PubMed 26707365
- Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NAFLD. N Engl J Med. 2024;390(6):497-509. · PubMed 38324483
- Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. · PubMed 37363821